X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Africa

Saama Launches Industry Changing Life Science Analytics Cloud

Yuvraj_pawp by Yuvraj_pawp
19th September 2017
in Africa, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Saama Technologies, Inc., a leading big data and advanced analytics solutions company, today announced the launch of its Life Science Analytics Cloud, which is designed to optimize clinical development processes and deliver outcomes by streamlining the steps of the entire clinical data journey. The suite offers a complete range of cloud-based clinical data analytics solutions for the Life Sciences industry.

As pharmaceutical companies struggle with the increase in drug development cycle times and cost overruns, pressure mounts for better command of the data that runs their business to make the drug development processes more efficient. A major challenge for any pharmaceutical company is the ability to leverage all the data it generates and has access to, due to data silos produced by a multi-vendor business model and disparate trial management systems.

Saama’s suite of analytics, powered by its Fluid Analytics Engine®, integrates multiple sources of structured and unstructured data. The cloud-based solution has pre-built capabilities for data ingestion, integration, and analysis, which can be leveraged to generate real-time business insights within weeks. Saama’s clients benefit from faster time-to-market, reduced costs, and better patient and business outcomes.

“We are committed to bringing our signature innovation and deep expertise to driving more efficient, optimized business processes and outcomes in the Life Sciences industry,” said Suresh Katta, CEO and founder of Saama Technologies. “We have been in the business of delivering superior business results for our clients and have spent considerable time and effort in developing a framework that can solve any data challenge. The launch of our Life Science Analytics Cloud marks a significant milestone in the progression of our company.”

Saama Life Science Analytics Cloud Modules
Clinical Development Optimizer: Clinical Development Optimizer (CDO) is a data lifecycle management solution that specializes in integrating and harmonizing data from disparate sources to create a clinical data lake where all the data resides, prepped and ready for analytics. CDO allows a clinical research team to assess risks across all studies and to evaluate performance based on key metrics.

Trial Planning Optimizer: Trial Planning Optimizer (TPO) is the clinical trial feasibility solution that optimizes the processes governing enrollment, investigator identification, site selection, and patient burden. TPO uses Real World Data (RWD) to identify eligible patient populations and principal investigators. TPO evaluates and quantifies the likelihood of successful patient enrollment and site selection.

Cohort Builder: Cohort Builder is the cohort generation solution that identifies patient populations based on inclusion-exclusion criteria. It organizes real-world patient information based on diagnosis, drug therapy, and procedures, to pinpoint population groups that fit specified criteria. Cohort Builder summarizes incidence rates and comorbidities of a disease and various other target metrics across a target cohort.

Market Analyzer: Market Analyzer is the commercialization analysis solution that provides the therapeutic value of clinical products, within a market basket and across geographic areas. The solution allows companies to predict the reception of a drug or treatment in the market on the basis of claims/EMR data and mapping it across similar products, market trends, and competitor activity.

Patient Pathways: Patient Pathways is the patient journey tracking solution that facilitates the evaluation of treatments, disease progression, outcomes, and total economic costs. Patient Pathways leverages RWD to provide decision-making insight into how a given disease is treated and/or managed; drug lines of therapy; treatment options and outcomes; cost of therapy; treating physicians; disease progression and complications.

“Saama’s revolutionary Life Science Analytics Cloud incorporates the latest techniques of deep learning and machine learning along with the industry’s foremost data ingestion and harmonization engine to deliver game-changing results for the industry”, said Karim Damji, SVP of Product Management and Marketing at Saama Technologies. “The launch of our Life Science Analytics Cloud is a natural progression from our previously announced innovative Clinical Data Analytics and Management as a Service announcement (CDaaS.) The analytics suite builds on top of a new consumption model for managing complexities of trial data and allows trial teams to focus on research and analysis vs. data-wrangling.”

With the release of the Life Science Analytics Cloud, Saama significantly opens up new possibilities for how to manage data in the life science industry.

Previous Post

Catalent To Acquire Cook Pharmica For $950 Million

Next Post

New Nymalize Oral Solution 10 mL Unit Dose for the Treatment of Subarachnoid Hemorrhage launched by Arbor Pharma

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

New Nymalize Oral Solution 10 mL Unit Dose for the Treatment of Subarachnoid Hemorrhage launched by Arbor Pharma

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In